Results 101 to 110 of about 25,234 (166)

"SGLT2 Inhibitor-Associated Diabetic Ketoacidosis in a Pediatric Patient: An Off- Label Use Case Report". [PDF]

Int Med Case Rep J
Aldossari BF, Aldossari S.
europepmc   +1 more source

SGLT2 inhibitor short-term efficacy and SYNTAX score association in coronary heart disease retinopathy: a propensity score matching study. [PDF]

Front Cardiovasc Med
Zhang Q, Wu Z, Jiang X, Wang Y, Xin Y, Guo X, Guo C.   +6 more
europepmc   +1 more source

SGLT2 independent effects of the SGLT2 inhibitor empagliflozin

This thesis explores how sodium glucose cotransporter 2 inhibitors (SGLT2i), particularly empagliflozin (EMPA), reduce cardiovascular risk by investigating their effects on cardiac infarction, hypertrophy, and heart failure (HF). SGLT2i demonstrate significant cardiovascular benefits across diabetic and non-diabetic populations, possibly through off ...
openaire   +2 more sources

The SGLT2 inhibitor empagliflozin promotes increased fatty acid oxidation in skeletal muscle cells. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Stevanovic S, Katare PB, Volledal HM, Bakke HG, Dolinar K, Pirkmajer S, Ouwens DM, Thoresen GH, Kase ET, Rustan AC.   +9 more
europepmc   +1 more source

Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL-HF. [PDF]

ESC Heart Fail
Elmegaard M, Køber L, Ersbøll MK, Lange T, Tuxen CD, Mouridsen MR, Lauridsen TK, Thune JJ, Jørgensen PG, Lamberts M, Dridi NP, Bonfils P, Petersen M, Stride NO, Barasa A, Jensen J, Garred C, Fosbøl E, Wolsk E, McMurray J, Petrie M, Schou M.   +21 more
europepmc   +1 more source

When Falls Reveal Acidosis: Unmasking Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. [PDF]

Cureus
Kaur J, Dogra A, Haymov A.
europepmc   +1 more source

SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis. [PDF]

Endocrinol Diabetes Metab Case Rep
Nagayama K, Harada R, Ajima H, Orikasa S, Aoshima M, Oki Y.   +5 more
europepmc   +1 more source

Evaluation of cardio-protective effects of a Novel SGLT2 inhibitor beyond glycemic control in preclinical models. [PDF]

Bioinformation
Kumar S, Prakash V, Kattimani R, Gupta S, Ravi R, Podder A.   +5 more
europepmc   +1 more source

Perioperative management with close renal function monitoring in a dental patient receiving SGLT2 inhibitor therapy for non-diabetic chronic kidney disease. [PDF]

J Dent Anesth Pain Med
Kira S, Arai C.
europepmc   +1 more source

Duration of DKA and Insulin Use in People with and Without SGLT2 Inhibitor Medications. [PDF]

Medicines (Basel)
Park YA, Lee AK, Barmanray RD, Gao F, Fourlanos S, Gilfillan C.   +5 more
europepmc   +1 more source